Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Lexaria Bioscience ( (LEXX) ).
Lexaria Bioscience has announced positive interim results from its Phase 1b study of DehydraTECH-semaglutide, showing a significant reduction in side effects compared to Rybelsus®, the only approved oral GLP-1 medication. The study indicates a 36.5% reduction in overall adverse events and a 43.5% reduction in gastrointestinal side effects, suggesting improved patient safety and tolerability. This development could enhance Lexaria’s position in the drug delivery market by offering a more tolerable alternative to existing treatments, potentially benefiting a large patient population and encouraging adherence to treatment protocols.
The most recent analyst rating on (LEXX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the delivery and effectiveness of active pharmaceutical ingredients. The company is known for its DehydraTECH technology, which aims to improve the performance of drugs across various therapeutic areas.
Average Trading Volume: 125,838
Technical Sentiment Signal: Sell
Current Market Cap: $19.13M
For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.